Cargando…

Podocyturia in Fabry disease: a 10-year follow-up

BACKGROUND: Fabry disease (FD) is a rare X-linked disorder of sphingolipid metabolism that results in chronic proteinuric nephropathy. Podocytes are one of the most affected renal cells and play an important role in the development and progression of kidney disease. Detached podocytes found in urine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vujkovac, Bojan, Srebotnik Kirbiš, Irena, Keber, Tajda, Cokan Vujkovac, Andreja, Tretjak, Martin, Radoš Krnel, Sandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824799/ https://www.ncbi.nlm.nih.gov/pubmed/35145641 http://dx.doi.org/10.1093/ckj/sfab172

Ejemplares similares

Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry Disease
por: Keber, Tajda, et al.
Publicado: (2017)

Urinary-derived extracellular vesicles reveal a distinct microRNA signature associated with the development and progression of Fabry nephropathy
por: Levstek, Tina, et al.
Publicado: (2023)

Biomarkers of Fabry Nephropathy: Review and Future Perspective
por: Levstek, Tina, et al.
Publicado: (2020)

Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
por: Cybulla, Markus, et al.
Publicado: (2022)

Increased urinary CD80 excretion and podocyturia in Fabry disease
por: Trimarchi, H., et al.
Publicado: (2016)

Polymorphisms of the PPAR-γ (rs1801282) and Its Coactivator (rs8192673) Have a Minor Effect on Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus
por: Pleskovič, Aleš, et al.
Publicado: (2016)

Urinary Extracellular Vesicles and Their miRNA Cargo in Patients with Fabry Nephropathy
por: Levstek, Tina, et al.
Publicado: (2021)

Vascular Endothelial Growth Factor Gene Polymorphism (rs2010963) and Its Receptor, Kinase Insert Domain-Containing Receptor Gene Polymorphism (rs2071559), and Markers of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus
por: Merlo, Sebastjan, et al.
Publicado: (2016)

Copious Podocyturia without Proteinuria and with Normal Renal Function in a Young Adult with Fabry Disease
por: Trimarchi, H., et al.
Publicado: (2015)

Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Podocyturia: Is there any clinical utility?
por: Yadav, I., et al.
Publicado: (2011)

Podocyturia: What is in a name?
por: Trimarchi, Hernán
Publicado: (2015)

Polymorphism rs5498 of the ICAM-1 gene affects the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus
por: Popović, Dražen, et al.
Publicado: (2016)

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy
por: Warnock, David G, et al.
Publicado: (2015)

Podocyturia: Potential applications and current limitations
por: Trimarchi, Hernán
Publicado: (2017)

Podocyturia: an earlier biomarker of cardiovascular outcomes
por: Eid, Assaad A., et al.
Publicado: (2022)

Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma
por: Cvenkel, Barbara, et al.
Publicado: (2015)

PECAM-1 gene polymorphism (rs668) and subclinical markers of carotid atherosclerosis in patients with type 2 diabetes mellitus
por: Popović, D, et al.
Publicado: (2016)

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
por: Goláň, Lubor, et al.
Publicado: (2015)

Optimization of pre‐analytical and analytical steps for DNA and RNA analysis of fresh cytology samples
por: Dolinar, Ana, et al.
Publicado: (2022)

Podocyturia: why it may have added value in rare diseases
por: Sanchez-Niño, Maria Dolores, et al.
Publicado: (2018)

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation
por: Warnock, David G., et al.
Publicado: (2012)

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
por: Linhart, Aleš, et al.
Publicado: (2023)

Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease
por: Trimarchi, H., et al.
Publicado: (2016)

MON-680 Might Podocyturia Be an Early Marker for Diabetic Nephropathy in Males
por: Durcan, Emre, et al.
Publicado: (2020)

Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
por: Wanner, Christoph, et al.
Publicado: (2020)

Podocyturia as a Diagnostic Marker for Preeclampsia amongst High-Risk Pregnant Patients
por: Jim, Belinda, et al.
Publicado: (2012)

Type 1 Kounis Syndrome in Patient with Idiopathic Anaphylaxis
por: Keber, Tajda, et al.
Publicado: (2017)

A Comparison of Podocyturia, Albuminuria and Nephrinuria in Predicting the Development of Preeclampsia: A Prospective Study
por: Jim, Belinda, et al.
Publicado: (2014)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Association of the ACE rs4646994 and rs4341 polymorphisms with the progression of carotid atherosclerosis in slovenian patients with type 2 diabetes mellitus
por: Merlo, S, et al.
Publicado: (2016)

Lipid profile in adult patients with Fabry disease - Ten-year follow up
por: Stepien, Karolina M., et al.
Publicado: (2017)

In Acute IgA Nephropathy, Proteinuria and Creatinine Are in the Spot, but Podocyturia Operates in Silence: Any Place for Amiloride?
por: Trimarchi, H., et al.
Publicado: (2017)

Effects of SGLT2 inhibitors on patients with diabetic kidney disease: A preliminary study on the basis of podocyturia
por: Durcan, Emre, et al.
Publicado: (2022)

Eight-Year Follow-Up of Neuropsychiatric Symptoms and Brain Structural Changes in Fabry Disease
por: Lelieveld, Irene M., et al.
Publicado: (2015)

Fabry disease in donor kidneys with 3- and 12-year follow-up after transplantation
por: Aasebø, Willy, et al.
Publicado: (2010)

Biomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up
por: Carnicer-Cáceres, Clara, et al.
Publicado: (2021)

The role of urine neutrophil gelatinase – associated lipocalin (NGAL) in acute heart failure in patients with ST – elevation myocardial infarction
por: Kirbiš, Simona, et al.
Publicado: (2015)

How important is evaluator's alignment for the reliability of assessment procedure for recognizing the good practice?
por: Rados Krnel, S, et al.
Publicado: (2023)

Hearing loss in fabry disease: A 16 year follow-up study of the Danish nationwide cohort
por: Yazdanfard, Puriya Daniel Würtz, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gnquqi8h70iu6lvhngu113nubq